Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Extended Half-Life Clotting Factors Cut Infusions, Hike Prices

Key clinical point: Extended half-life clotting factors cut infusion frequency but cost much more.

Major finding: Extended half-life factor IX halved the number infusions, but increased the cost from $697,497 to more than $1 million in a year.

Study details: The study examined usage patterns in nearly 8,000 patients over 18 months.

Disclosures: The study was funded HTRS/ATHN Dataset Research Engagement and a DREAM Award from the Hemostasis and Thrombosis Research Society. Dr. Croteau reported consulting for Bayer, Bioverativ, Biomarin, CSL-Behring, and other companies.

Citation:

Croteau SE et al. Haemophilia. 2019. doi: 10.1111/hae.13758.